NEW YORK: Pfizer says its vaccine continues to be efficient towards COVID-19 as much as six months later.
Pfizer and its German accomplice, BioNTech, introduced up to date outcomes Thursday from their ongoing late-stage examine of greater than 44,000 volunteers.
The businesses stated the vaccine was 91% efficient towards symptomatic illness and was much more protecting in stopping extreme illness. Of 927 confirmed COVID-19 instances detected by means of March 13, 77 had been amongst individuals who obtained the vaccine and 850 had been amongst individuals who obtained dummy photographs.
There have been no severe security considerations and the vaccine additionally appeared to work towards a variant first detected in South Africa, the businesses stated.
The U.Ok. and U.S. gave the emergency inexperienced gentle to roll out Pfizer’s vaccine late final yr adopted by many different nations. The vaccine is allowed for ages 16 and up.
This week, the businesses stated the vaccine is protected and strongly protecting in youngsters as younger as 12, based mostly on a examine of two,260 U.S. volunteers.
